Hypercalcemia of malignancy: diagnosis and therapy

Area of Science:

• Oncology
• Nephrology
• Endocrinology

Background:

• Hypercalcemia is a common complication of malignancy.
• Effective management is crucial for patient comfort and prognosis.

Purpose of the Study:

• To outline an effective therapeutic strategy for managing hypercalcemia of malignancy.
• To detail the sequence and agents used in treatment.

Main Methods:

• Initiate vigorous intravenous hydration with normal saline (300-500 mL/h).
• Administer intravenous furosemide as needed to prevent fluid overload.
• Add subcutaneous calcitonin and oral prednisone if hypercalcemia persists after hydration.
• Consider plicamycin for refractory cases, avoiding prostaglandin synthetase inhibitors and investigational bisphosphonates.

Main Results:

• Vigorous hydration is the primary and most effective approach.
• Combination therapy with calcitonin and prednisone often yields a prompt response.
• Plicamycin provides an option for persistent hypercalcemia in non-terminal patients.

Conclusions:

• Individualized, stepwise management is key for hypercalcemia of malignancy.
• Early hydration followed by targeted pharmacotherapy and malignancy treatment improves outcomes.
• Current recommendations prioritize established therapies over investigational agents.